Cargando…

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer

BACKGROUND: Close to three-quarters of ovarian cancer cases are frequently diagnosed at an advanced stage, with more than 70% of them failing to respond to primary therapy and relapsing within 5 years. There is an urgent need to identify strategies for early detection of ovarian cancer recurrence, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Jin, Sokoll, Lori J., Zhang, Zhen, Chan, Daniel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291808/ https://www.ncbi.nlm.nih.gov/pubmed/37357306 http://dx.doi.org/10.1186/s12014-023-09414-z

Ejemplares similares

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays
por: Song, Jin, et al.
Publicado: (2021)

Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
por: Guo, Jing, et al.
Publicado: (2019)

Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
por: Wang, Fei, et al.
Publicado: (2018)

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011)

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2021)

A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma
por: Song, Jin, et al.
Publicado: (2019)

CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer
por: Singha, Bipradeb, et al.
Publicado: (2018)

Reply to Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer
por: Guo, Jing, et al.
Publicado: (2019)

The Role of (18)F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels
por: Cengiz, Arzu, et al.
Publicado: (2019)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis
por: Guo, Junhong, et al.
Publicado: (2017)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer
por: Koh, Stephen Chee Liang, et al.
Publicado: (2012)

High preoperative serum sVCAM-1 concentration as a predictor of early ovarian cancer recurrence
por: Jakimovska, Marina, et al.
Publicado: (2020)

Rising CA-125 (Cancer Antigen 125) Levels: Cancer Recurrence or a Vaccine Reaction?
por: Parkash, Jasmita, et al.
Publicado: (2023)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer
por: Mor, Gil, et al.
Publicado: (2019)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
por: Dunton, Charles J., et al.
Publicado: (2021)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
por: Zheng, Li-e, et al.
Publicado: (2016)

Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125
por: Bayoumy, Sherif, et al.
Publicado: (2020)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer
por: Yang, Zhi-jun, et al.
Publicado: (2016)

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

The effect of CA125 on metastasis of ovarian cancer: old marker new function
por: Yuan, Qin, et al.
Publicado: (2017)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2020)

Value of serum miR-21, HE4 and CA125 in surveillance for postoperative recurrent or metastatic ovarian cancer
por: Gong, Zhenying, et al.
Publicado: (2022)

CT-guided (125)I brachytherapy for recurrent ovarian cancer
por: Liu, Ping, et al.
Publicado: (2017)

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
por: Jiang, Qin, et al.
Publicado: (2021)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study
por: Funston, Garth, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5fn4pv1rucpol1r4a9m4n49jus